Current treatment options for secondary hyperparathyroidism in patients with stage 3 to 4 chronic kidney disease and vitamin D deficiency
Andrea Galassi(University of Milan), Mario Cozzolino(AOL (United States)), Paola Ciceri(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Michela Frittoli(University of Milan), Giulia Porata(Azienda Socio Sanitaria Territoriale Santi Paolo e Carlo), Giulia Boni Brivio(University of Milan), Andrea Stucchi(Azienda Socio Sanitaria Territoriale Santi Paolo e Carlo), Anila Cara(University of Milan), Lorenza Magagnoli(AOL (United States)), Rossella Iatrino(Azienda Socio Sanitaria Territoriale Santi Paolo e Carlo), Eliana Fasulo(Azienda Socio Sanitaria Territoriale Santi Paolo e Carlo)
Cited by 10
Related Papers
37th International Symposium on Intensive Care and Emergency Medicine (part 2 of 3)
|Critical Care|2017|61
Effects of a medium cut-off (Theranova®) dialyser on haemodialysis patients: a prospective, cross-over study
|Clinical Kidney Journal|2019|50
Association between CKD-MBD and mortality in older patients with advanced CKD—results from the EQUAL study
|Nephrology Dialysis Transplantation|2023|37
Choice of the Dialysis Modality: Practical Considerations
|Journal of Clinical Medicine|2023|30
Secondary hyperparathyroidism in chronic kidney disease: pathophysiology, current treatments and investigational drugs
|Expert Opinion on Investigational Drugs|2024|24